ID29063A - DISCLOSURE FORMATION OF VASCULAR HIPERPERMEABILITY - Google Patents

DISCLOSURE FORMATION OF VASCULAR HIPERPERMEABILITY

Info

Publication number
ID29063A
ID29063A IDW00200101000A ID20011000A ID29063A ID 29063 A ID29063 A ID 29063A ID W00200101000 A IDW00200101000 A ID W00200101000A ID 20011000 A ID20011000 A ID 20011000A ID 29063 A ID29063 A ID 29063A
Authority
ID
Indonesia
Prior art keywords
tyrosine kinase
vascular
events
hiperpermeability
formation
Prior art date
Application number
IDW00200101000A
Other languages
Indonesian (id)
Inventor
Lee D Arnold
Peter F Bousquet
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID29063A publication Critical patent/ID29063A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

Vascular hyperpermeability in individuals is a prelude to a number of physiological events that are often deleterious. Among these events is the formation of edema, diapedesis, aberrant trans-endothelial exchange, extravasation, exudation and effusion, matrix deposition (often with abnormal stromal proliferation) and vascular hypotension. Vascular hyperpermeability and the subsequent events can be inhibited by the administration of a compound that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. Preferred administered compounds selectively inhibit the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGF tyrosine kinase receptor.
IDW00200101000A 1998-11-06 1999-11-03 DISCLOSURE FORMATION OF VASCULAR HIPERPERMEABILITY ID29063A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10746298P 1998-11-06 1998-11-06

Publications (1)

Publication Number Publication Date
ID29063A true ID29063A (en) 2001-07-26

Family

ID=22316735

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101000A ID29063A (en) 1998-11-06 1999-11-03 DISCLOSURE FORMATION OF VASCULAR HIPERPERMEABILITY

Country Status (19)

Country Link
EP (1) EP1126842A2 (en)
JP (1) JP2002529421A (en)
KR (1) KR20010080952A (en)
CN (1) CN1342077A (en)
AR (1) AR023912A1 (en)
AU (1) AU1908000A (en)
BG (1) BG105476A (en)
BR (1) BR9915139A (en)
CA (1) CA2347916A1 (en)
CO (1) CO5150183A1 (en)
CZ (1) CZ20011564A3 (en)
HU (1) HUP0104302A3 (en)
ID (1) ID29063A (en)
IL (1) IL142583A0 (en)
NO (1) NO20012218L (en)
PL (1) PL348163A1 (en)
SK (1) SK5052001A3 (en)
TR (1) TR200102278T2 (en)
WO (1) WO2000027414A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143596A0 (en) * 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
ES2377847T3 (en) 1999-01-13 2012-04-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU781444B2 (en) * 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
DE10021246A1 (en) * 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
CA2454976C (en) * 2001-07-26 2011-05-10 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
SI1478358T1 (en) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
DK2949658T3 (en) 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
DK1626714T3 (en) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurine drugs for diseases mediated by PDGFR
RS52625B (en) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
KR20150072458A (en) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
US8546349B2 (en) 2010-07-28 2013-10-01 Thermo Fisher Scientific Biosciences Inc. siRNA targeting VEGFA and methods for treatment in vivo
KR101565886B1 (en) 2013-10-23 2015-11-05 전남대학교산학협력단 Method and Kit for Diagnosting of Ovarian Hyperstimulation Syndrome
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
CN106381330A (en) * 2016-08-30 2017-02-08 张建华 Primer and kit for detecting susceptibility of communicating hydrocephalus
CN112055718A (en) * 2018-03-19 2020-12-08 药物抗体公司 anti-VEGFR-2 antibodies
CN109718253B (en) * 2019-01-16 2021-09-24 中国人民解放军总医院 Use of bacteria capable of metabolizing to produce histamine for preventing or treating altitude sickness

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789948A (en) * 1971-10-13 1973-04-11 Sandoz Sa NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US3843664A (en) * 1973-02-20 1974-10-22 Sandoz Ag Substituted naphtho pyrazoles
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
FR2742662B1 (en) * 1995-12-21 1998-01-23 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE19638745C2 (en) * 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
DE69818083T2 (en) * 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO [1,2-c] -, NAPHTHO [1,2-C] AND BENZO [6,7] CYCLOHEPTA [1,2-c] PYRAZOLE DERIVATIVES
EP1021182A1 (en) * 1997-10-06 2000-07-26 Basf Aktiengesellschaft Indeno[1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity
PT1073435E (en) * 1998-04-30 2004-10-29 Abbott Gmbh & Co Kg SUBSTITUTED TRYCYCLIC DERIVATIVES OF PYRAZOLE WITH PROTEIN KINASE ACTIVITY

Also Published As

Publication number Publication date
BG105476A (en) 2002-02-28
HUP0104302A3 (en) 2002-11-28
IL142583A0 (en) 2002-03-10
SK5052001A3 (en) 2002-10-08
PL348163A1 (en) 2002-05-06
NO20012218L (en) 2001-06-18
JP2002529421A (en) 2002-09-10
KR20010080952A (en) 2001-08-25
AU1908000A (en) 2000-05-29
CN1342077A (en) 2002-03-27
CA2347916A1 (en) 2000-05-18
WO2000027414A2 (en) 2000-05-18
CZ20011564A3 (en) 2002-04-17
TR200102278T2 (en) 2001-12-21
HUP0104302A2 (en) 2002-03-28
CO5150183A1 (en) 2002-04-29
BR9915139A (en) 2001-08-07
EP1126842A2 (en) 2001-08-29
NO20012218D0 (en) 2001-05-04
WO2000027414A3 (en) 2000-09-08
AR023912A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
ID29063A (en) DISCLOSURE FORMATION OF VASCULAR HIPERPERMEABILITY
EA200100579A1 (en) QUINOLINE AND QUINOXALINE COMPOUNDS AS A PDGF RECEPTOR AND / OR TYROSINKINASE LCK INHIBITORS
Bulanova et al. Extracellular ATP induces cytokine expression and apoptosis through P2X7 receptor in murine mast cells
Chen et al. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin
Karalliedde et al. Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes
MA28038A1 (en) THIENOPYRAZOLES
EA199901092A1 (en) QUINOLINE AND QUINOXALINE COMPOUNDS INHIBITING THROMBOTYTIC GROWTH FACTOR AND / OR p56lck THYROZYNKINAS
WO2004084824A3 (en) Biaryl substituted 6-membered heterocyles as sodium channel blockers
BR0312648A (en) Process for preparing certain pyrrole triazine compounds
DE60043397D1 (en) CYTOKINE, PARTICULAR TNF-ALPHA, HEMMER
RS20050042A (en) Novel inhibitors of kinases
NO20091374L (en) Pyrrolotriazine kinase inhibitors
Salomonsson et al. Calcium recruitment in renal vasculature: NE effects on blood flow and cytosolic calcium concentration
Levick et al. Substance P-mediated cardiac mast cell activation: An in vitro study
MA29498B1 (en) PYRAZOLOPYRIDINE DERIVATIVES AS BETA-ADRENERGIC RECEPTOR KINASE INHIBITORS 1
Lou et al. Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR-positive lung adenocarcinoma patients: updated data and exploratory in vitro study
Weinstock The presynaptic effect of β-adrenoceptor antagonists on noradrenergic neurones
DK1147088T3 (en) 6-arylphenanthridines with PDE-IV inhibitory activity
Cox et al. Prejunctional angiotensin receptors involved in the facilitation of noradrenaline release in mouse tissues
Piotrkowski et al. Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney
Chalmers et al. Hypertension in the elderly: the role of calcium antagonists
Dustan Calcium channel blockers. Potential medical benefits and side effects.
PL1622881T3 (en) Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect
Igarashi et al. Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats
MEP49108A (en) Substituted spirobenzazepines